cp-55,940 has been researched along with hu 308 in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Almehizia, AA; Alqarni, MH; Bartlow, P; Cao, H; Cheng, T; Feng, R; Gao, Y; Gertsch, J; Kurihara, N; Myint, KZ; Roodman, GD; Teramachi, J; Tong, Q; Wang, L; Xie, XQ; Yang, P | 1 |
| Almehizia, AA; Alqarni, MH; Feng, R; Myint, KZ; Ouyang, Q; Tong, Q; Wang, L; Xie, XQ; Yang, P | 1 |
| Buzard, DJ; Han, S; Jones, RM; Thatte, J | 1 |
| Cheng, J; Duan, W; Hua, T; Li, F; Liu, ZJ; Nie, H; Sun, Y; Wang, H; Wu, M; Xu, Y; Yang, L; Zhang, T; Zhang, Z | 1 |
1 review(s) available for cp-55,940 and hu 308
| Article | Year |
|---|---|
Therapeutic utility of cannabinoid receptor type 2 (CB(2)) selective agonists.
Topics: Animals; Drug Design; Humans; Ligands; Models, Molecular; Molecular Conformation; Receptor, Cannabinoid, CB2; Structure-Activity Relationship; Substrate Specificity | 2013 |
3 other study(ies) available for cp-55,940 and hu 308
| Article | Year |
|---|---|
Lead discovery, chemistry optimization, and biological evaluation studies of novel biamide derivatives as CB2 receptor inverse agonists and osteoclast inhibitors.
Topics: Alkylation; Animals; Benzeneacetamides; Binding, Competitive; Bone Marrow; Cell Death; Cells, Cultured; CHO Cells; Cricetinae; Cyclic AMP; High-Throughput Screening Assays; Humans; Models, Molecular; Molecular Structure; Osteoclasts; Osteogenesis; Receptor, Cannabinoid, CB2; Structure-Activity Relationship | 2012 |
Novel triaryl sulfonamide derivatives as selective cannabinoid receptor 2 inverse agonists and osteoclast inhibitors: discovery, optimization, and biological evaluation.
Topics: Animals; Biological Assay; Cannabinoid Receptor Agonists; CHO Cells; Cricetinae; Ligands; Macrophages; Mice; Osteoclasts; Quantitative Structure-Activity Relationship; Receptor, Cannabinoid, CB2; Sulfonamides | 2013 |
Carbon-silicon switch led to the discovery of novel synthetic cannabinoids with therapeutic effects in a mouse model of multiple sclerosis.
Topics: Animals; Cannabinoids; Carbon; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Discovery; Encephalomyelitis, Autoimmune, Experimental; Male; Mice; Mice, Inbred C57BL; Molecular Structure; Multiple Sclerosis; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Silicon; Structure-Activity Relationship | 2021 |